for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arvinas Inc

ARVN.OQ

Latest Trade

24.63USD

Change

0.14(+0.57%)

Volume

18,987

Today's Range

24.27

 - 

25.10

52 Week Range

10.22

 - 

28.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
24.49
Open
24.67
Volume
18,987
3M AVG Volume
4.26
Today's High
25.10
Today's Low
24.27
52 Week High
28.21
52 Week Low
10.22
Shares Out (MIL)
33.72
Market Cap (MIL)
1,651.48
Forward P/E
-11.36
Dividend (Yield %)
--

Latest Developments

More

Arvinas Inc- QTRLY Loss Per Share $0.55

Arvinas Says Under Terms Of Bayer Agreement, Co Will Receive Upfront Payment Of $17.5 Mln Within 30 Days Of The Effective Date

Bayer And Arvinas To Develop Novel Proteolysis-Targeting Chimera Candidates For Humans And Plants

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arvinas Inc

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.

Industry

Biotechnology & Drugs

Contact Info

5 Science Park

+1.203.5351456

http://arvinas.com/

Executive Leadership

Timothy Shannon

Independent Chairman of the Board

John G. Houston

President, Chief Executive Officer, Director

Sean A. Cassidy

Chief Financial Officer

Andrew Crew

Chief Technology Officer

Ian Taylor

Chief Scientific Officer

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-4.400

2019(E)

-2.155
Price To Earnings (TTM)
--
Price To Sales (TTM)
111.22
Price To Book (MRQ)
6.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.78
LT Debt To Equity (MRQ)
1.72
Return on Investment (TTM)
-50.92
Return on Equity (TTM)
-43.91

Latest News

Bayer teams up with biotech firm Arvinas in deal worth up to $750 mln

German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up